Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Compass Therapeutics Inc shares valued at $21,100 were purchased by Schuetz Thomas J. on May 27 ’25. At $2.11 per share, Schuetz Thomas J. acquired 10,000 shares. The insider’s holdings grew to 6,480,825 shares worth approximately $20.28 million following the completion of this transaction.
Also, GORDON CARL L sold 3,571,428 shares, netting a total of over 5,678,571 in proceeds. Following the sale of shares at $1.59 each, the insider now holds 0 shares.
Before that, ORBIMED ADVISORS LLC had sold 3,571,428 shares from its account. In a trade valued at $5,678,571, the Director traded Compass Therapeutics Inc shares for $1.59 each. Upon closing the transaction, the insider’s holdings decreased to 3,571,428 shares, worth approximately $0.0.
Analysts at Leerink Partners upgraded the stock from ‘”a Market perform”‘ to ‘”an Outperform”‘ outlook in a report released in early April. As of February 24, 2025, Guggenheim has initiated its “Buy” rating for CMPX. Earlier on February 19, 2025, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for CMPX stock.
Analyzing CMPX Stock Performance
On last trading session,, Compass Therapeutics Inc [NASDAQ: CMPX] rose 5.03% to $3.13. The stock’s lowest price that day was $2.975, but it reached a high of $3.18 in the same session. During the last five days, there has been a surge of approximately 14.23%. Over the course of the year, Compass Therapeutics Inc shares have jumped approximately 189.81%. Shares of the company reached a 52-week high of $4.08 on 02/11/25 and a 52-week low of $1.33 on 04/01/25.
Support And Resistance Levels for Compass Therapeutics Inc (CMPX)
According to the 24-hour chart, there is a support level at 3.01, which, if violated, would cause prices to drop to 2.88. In the upper region, resistance lies at 3.22. The next price resistance is at 3.30. RSI (Relative Strength Index) is 71.17 on the 14-day chart, showing overbought technical sentiment.
Is Compass Therapeutics Inc subject to short interest?
Stocks of Compass Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.48 million shares to 7.39 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 6.91 million shares. A jump of 6.45% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.27 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.27.
Which companies own the most shares of Compass Therapeutics Inc (CMPX)?
In terms of Compass Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 101.34% from the previous closing price of $2.98. Analysts anticipate Compass Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 6. In spite of this, 2 analysts ranked Compass Therapeutics Inc stock as Buy at the end of 2025. On December 23, 2024, D. Boral Capital assigned a price target of “a Buy” to the stock and initiated coverage with a $32.
